Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

8.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.2K
GPCR Desensitization01:12

GPCR Desensitization

8.7K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.7K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

19.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.5K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

7.4K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
7.4K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

134.0K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
134.0K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

6.9K
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular Hyporesponsiveness in Sepsis Is Associated With Nitric Oxide-Dependent Activation of G-Protein Receptor Kinase.

Journal of cardiovascular pharmacology·2026
Same author

Effect of the Y<sub>2</sub>O<sub>3</sub> Promoter on the Structure of the Ni/Al<sub>2</sub>O<sub>3</sub> Catalyst for Ethanol Autothermal Reforming.

ACS omega·2026
Same author

Experience of parenting children and adolescents with cystic fibrosis: A systematic review of qualitative studies and meta-synthesis.

Respiratory medicine·2025
Same author

Deciphering complexity of GPCR signaling and modulation: implications and perspectives for drug discovery.

Clinical science (London, England : 1979)·2025
Same author

Sustained Gα<sub>s</sub> signaling mediated by vasopressin type 2 receptors is ligand dependent but endocytosis and β-arrestin independent.

Science signaling·2025
Same author

Catalytic Pt/Al<sub>2</sub>O<sub>3</sub> Monolithic Foam for Ethanol Reforming Fabricated by the Competitive Impregnation Method.

ACS omega·2023

Related Experiment Video

Updated: Mar 26, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K

Recent updates on GPCR biased agonism.

André S Pupo1, Diego A Duarte2, Vanessa Lima3

  • 1Department of Pharmacology, Instituto de Biociências, UNESP, Botucatu, SP, Brazil.

Pharmacological Research
|February 3, 2016
PubMed
Summary
This summary is machine-generated.

Biased agonism in G protein-coupled receptors (GPCRs) allows drugs to selectively activate specific signaling pathways. This review explores recent findings and therapeutic potential of biased agonists for targeted drug discovery.

Keywords:
7TMRFunctional selectivityGPCR

More Related Videos

Parallel Interrogation of &#946;-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

14.1K
Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.5K

Related Experiment Videos

Last Updated: Mar 26, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K
Parallel Interrogation of &#946;-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

14.1K
Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.5K

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Drug Discovery

Background:

  • G protein-coupled receptors (GPCRs) are crucial drug targets, with ~40% of marketed drugs acting on them.
  • Biased agonism, preferential activation of specific signaling pathways by ligands, is a key area in GPCR research.

Purpose of the Study:

  • To review recent advancements in biased agonism of GPCRs.
  • To discuss the extension of biased agonism to intracellular signaling and allosterism.
  • To explore strategies for assessment and therapeutic applications of biased agonists.

Main Methods:

  • Literature review of recent findings on GPCR biased agonism.
  • Analysis of signaling pathways and allosteric modulation.
  • Evaluation of therapeutic strategies and assessment methods.

Main Results:

  • Biased agonism extends beyond traditional pathways to intracellular signaling.
  • Allosterism plays a significant role in biased agonism.
  • Novel strategies for assessment and interpretation of biased agonism are emerging.

Conclusions:

  • Biased agonism offers a promising avenue for developing more selective and effective therapeutics.
  • Understanding biased agonism can lead to improved drug targeting and reduced side effects.
  • Further research into biased agonists holds significant therapeutic potential.